The MAPP research network: a novel study of urologic chronic pelvic pain syndromes.

Permalink
https://escholarship.org/uc/item/5724h7r6

Journal
BMC urology, 14(1)

ISSN
1471-2490

Authors
Clemens, J Quentin
Mullins, Chris
Kusek, John W
et al.

Publication Date
2014-08-01

DOI
10.1186/1471-2490-14-57

Peer reviewed
The MAPP research network: a novel study of urologic chronic pelvic pain syndromes

J Quentin Clemens1*, Chris Mullins2, John W Kusek2, Ziya Kirkali2, Emeran A Mayer3, Larissa V Rodríguez3, David J Klumpp4, Anthony J Schaeffer4, Karl J Kreder5, Dedra Buchwald6, Gerald L Andriole7, M Scott Lucia8, J Richard Landis9, Daniel J Clauw10 and The MAPP Research Network Study Group

Abstract

Urologic chronic pelvic pain syndrome (UCPPS) may be defined to include interstitial cystitis/bladder pain syndrome (IC/BPS) and chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). The hallmark symptom of UCPPS is chronic pain in the pelvis, urogenital floor, or external genitalia often accompanied by lower urinary tract symptoms. Despite numerous past basic and clinical research studies there is no broadly identifiable organ-specific pathology or understanding of etiology or risk factors for UCPPS, and diagnosis relies primarily on patient reported symptoms. In addition, there are no generally effective therapies. Recent findings have, however, revealed associations between UCPPS and “centralized” chronic pain disorders, suggesting UCPPS may represent a local manifestation of more widespread pathology in some patients. Here, we describe a new and novel effort initiated by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the U.S. National Institutes of Health (NIH) to address the many long standing questions regarding UCPPS, the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network. The MAPP Network approaches UCPPS in a systemic manner, in which the interplay between the genitourinary system and other physiological systems is emphasized. The network’s study design expands beyond previous research, which has primarily focused on urologic organs and tissues, to utilize integrated approaches to define patient phenotypes, identify clinically-relevant subgroups, and better understand treated natural history and pathophysiology. Thus, the MAPP Network provides an unprecedented, multi-layered characterization of UCPPS. Knowledge gained is expected to provide important insights into underlying pathophysiology, a foundation for better segmenting patients for future clinical trials, and ultimately translation into improved clinical management. In addition, the MAPP Network’s integrated multi-disciplinary research approach may serve as a model for studies of urologic and non-urologic disorders that have proven refractory to past basic and clinical study.

Trial registration: ClinicalTrials.gov identifier: NCT01098279 “Chronic Pelvic Pain Study of Individuals with Diagnoses or Symptoms of Interstitial Cystitis and/or Chronic Prostatitis (MAPP-EP)”.

Keywords: Urological chronic pelvic pain syndromes, Interstitial cystitis, Chronic prostatitis, Translational research, Multi-disciplinary

Background

Urologic chronic pelvic pain syndrome (UCPPS) encompasses two highly prevalent non-malignant urologic disorders, interstitial cystitis/bladder pain syndrome (IC/BPS) and chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). UCPPS is primarily characterized by chronic and often debilitating pain in the pelvic region and/or genitalia and typically a spectrum of defects in bladder and lower urinary tract function [1,2].

Numerous studies have been conducted over the past two decades to define the pathophysiology and natural history of UCPPS and to examine the efficacy of therapies. Many of those studies were supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the U.S. National Institutes of Health (NIH). The first NIDDK-sponsored pelvic pain clinical research network, the Interstitial Cystitis Database study (ICDB) was initiated in 1991 [3]. This five-year prospective cohort
study collected data on more than 600 persons and characterized them across demographic and clinical characteristics, including bladder biopsy [4]. The Interstitial Cystitis Clinical Trials Group (ICCTG) was subsequently established to conduct randomized clinical trials beginning in 1996 [5-9]. In 2003, this group became the Interstitial Cystitis Collaborative Research Network (ICCRN) and carried out additional randomized clinical trials [10-12]. In 1998, the Chronic Prostatitis Cohort (CPC) study began to prospectively collect patient data to systematically examine the demographics, clinical characteristics and natural history of CP/CPPS [13]. The NIDDK subsequently initiated the Chronic Prostatitis Collaborative Research Network (CPCRN) which performed clinical trials for CP/CPPS [14-17]. Results from these clinical research studies failed to identify definitive risk factors or generally effective treatments, with the exception of a single study suggesting that myofascial physical therapy might be effective in IC/BPS [18]. The NIDDK-supported Boston Area Community Health (BACH) Survey [19-21] and the RAND IC Epidemiology (RICE) Study [22,23] provided estimates on the prevalence of IC-related symptoms for both men and women, as well as an expanded understanding of symptom morbidity. In addition to these clinical and epidemiological studies, many basic research efforts were developed to describe pathophysiology at the cellular level, including in vivo studies of model systems. However, no consensus agreement has been achieved on an underlying etiology for UCPPS, though co-occurrence of UCPPS with other chronic non-urologic pain syndromes has been revealed [24-30].

In light of the limitations of previous studies and results showing potential associations between UCPS and other chronic pain conditions, the NIDDK proposes that the traditional bladder and prostate centered focus of UCPS research be broadened to a systemic view of disease in which the interplay between the genitourinary system and other physiological systems (e.g., the central nervous system), is highlighted. Additionally, it is suggested that studies of UCPS would benefit from incorporating broad approaches involving a diversity of urologic and non-urologic disciplines to promote a more comprehensive characterization of patient phenotype. These concepts, as well as recommendations solicited from the scientific community [31], prompted the NIDDK to initiate a new research program for the study of UCPS, the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network. Since its inception in 2008, the MAPP Research Network has adopted a highly collaborative and integrated research strategy that incorporates new and novel approaches conducted by investigators representing traditional urologic disciplines and broad non-urologic expertise, including experts in pain research, neurobiology and neuroimaging, infectious disease, biomarker discovery, animal modeling, epidemiology, psychology, immunology, among many others. The overarching goal of the MAPP Research Network is to provide findings useful for designing future clinical trials and ultimately to improve clinical management for UCPS patients. Importantly, the design and goals of the MAPP Network are complementary to other large phenotyping efforts for non-urologic pain conditions being conducted, such as the OPPERA study [32].

The MAPP Research Network includes six Discovery Sites and several specialized sub-sites that conduct multiple, collaborative Trans-MAPP (i.e., across sites) studies, as well as a number of single-site studies, and two specialized Cores (see Acknowledgement for complete listing of MAPP Network Sites and affiliated personnel). The Data Coordination Core (DCC) serves as the central site for data acquisition and storage; provides bio-statistical analyses for all studies; and promotes network-wide quality assurance. The DCC also provides administrative support, including development and maintenance of a public website (http://www.mappnetwork.org/). The Tissue Analysis and Technology Core (TATC) monitors biosample collection and provides sample banking, annotation, and distribution services.

The MAPP Research Network is currently conducting complementary basic, translational, and clinical science studies to investigate questions of significant clinical relevance and adopts the view that UCPS potentially involves significant systemic contributions. The primary scientific protocol is a prospective observational study of the treated natural history UCPS, the Trans-MAPP Epidemiology/Phenotyping (EP) Study. A full description of the central Trans-MAPP EP Study and the complement of urologic and non-urologic measures employed are described in the companion report by Landis et al. [33]. In addition to the extensive phenotyping, the Trans-MAPP EP Study also provide a source of highly characterized participants for further phenotyping through other integrated network protocols. Assembled network working groups develop and conduct complementary Trans-MAPP studies that broadly address potential contributions of various physiological systems and hypotheses of underlying etiology, pathophysiology, risk, and relationships between UCPS and commonly associated non-urologic syndromes. These include structural and functional assessments of the central nervous system; efforts to uncover potential contributions of infectious agents to etiology; discovery efforts to identify new biological markers; extensive characterizations of symptom variation (e.g., flares); and efforts to develop new and more informative patient reported outcome measures. The network is also engaged in collaborative research to establish and assess animal models validated for the presence of clinically-relevant phenotypes, thus allowing for improved translation between
animal and human studies. The MAPP study will provide comprehensive, state-of-the-art phenotyping data which will set the standard for future UCPPS research. Results from the MAPP study can be integrated with other, more clinically focused phenotyping efforts (such as the UPOINT system [34,35]) to better define the ‘minimal data set’ required to provide optimal patient care for UCPPS patients.

Within the MAPP Research Network all clinical TransMAPP protocols and site-specific efforts, which primarily serve to pilot test ideas complementary to the collaborative protocols, are highly integrated through their use of shared patients and controls evaluated through standard phenotyping; common biological samples; and a standardized data collection, storage, and analysis strategy. In addition, neuroimaging study parameters are standardized across sites and scan data is centrally managed by the University of California at Los Angeles (UCLA) Center for Neurobiology of Stress (painrepository.org), in close collaboration with UCLA-Laboratory of Neuroimaging (LONI), which has extensive experience in the collection, storage and analysis of large multi-site MRI data sets (loni.usc.edu). In this way diverse findings across protocols may be integrated to allow a detailed characterization of a single UCPPS patient or patient sub-groups. Importantly, these efforts are also generating a unique national resource of highly detailed longitudinal clinical and epidemiological data associated with data from additional, integrated phenotyping studies and linked biological samples, for future use by the wider research community through the NIDDK Data and Sample Repositories (http://www3.niddk.nih.gov/researchprograms/repositories/).

Conclusions
UCPPS research is clearly at a cross-road in which the traditional basic and clinical scientific strategies are being re-evaluated in light of evolving ideas of UCPPS and recognition of the limitations of previous study designs. The MAPP Research Network was created to address these challenges. Advances from network efforts are expected to provide a more comprehensive understanding of UCPPS pathophysiology, identify clinically relevant patient sub-groups, inform the design of future clinical trials, and ultimately improve clinical care. The unique organization and approach of the MAPP Network may also provide a blueprint for multi-site, multi-disciplinary research in the broader pain field, as well as for those disciplines addressing other disorders with ill-defined pathophysiology.

Appendix: MAPP Research Network Study Group

MAPP Network Executive Committee
J. Quentin Clemens, MD, FACS, MSci, Network Chair, 2013-Philip Hanno, MD
Ziya Kirkali, MD
John W. Kusek, PhD
J. Richard Landis, PhD
M. Scott Lucia, MD
Chris Mullins, PhD
Michel A. Pontari, MD

Northwestern University Discovery Site
David J. Klumpp, PhD, Co-Director
Anthony J. Schaeffer, MD, Co-Director
Apkar (Vania) Apkarian, PhD
David Cella, PhD
Melissa A. Farmer, PhD
Colleen Fitzpatrick, MD
Richard Gershon, PhD
James W. Griffith, PhD
Charles J. Heckman II, PhD
Mingchen Jiang, PhD
Laurie Keefer, PhD
Darlene S. Marko, RN, BSN, CCRC
Jean Michniewicz
Todd Parrish, PhD
Frank Tu, MD, MPH

University of California, Los Angeles Discovery Site and PAIN Neuroimaging Core
Emeran A. Mayer, MD, Co-Director
Larissa V. Rodriguez, MD, Co-Director
Jeffry Alger, PhD
Cody P. Ashe-McNalley
Ben Ellingson, PhD
Nuwanthi Heendeniya
Lisa Kilpatrick, PhD
Jason Kutch, PhD
Jennifer S. Labus, PhD
Bruce D. Naliboff, PhD
Fornessa Randal
Suzanne R. Smith, RN, NP

University of Iowa Discovery Site
Karl J. Kreder, MD, MBA, Director
Catherine S. Bradley, MD, MSCE
Mary Eno, RN, RA II
Kris Greiner, BA
Yi Luo, PhD, MD
Susan K. Lutgendorf, PhD
Michael A. O’Donnell, MD
Barbara Ziegler, BA

University of Michigan Discovery Site
Daniel J. Clauw, MD, Co-Director;
Network Chair, 2008-2013
J. Quentin Clemens, MD, FACS, MSci,
Co-Director; Network Chair, 2013-
Suzie As-Sanie, MD
Sandra Berry, MA
Megan E. Halvorson, BS, CCRP
Richard Harris, PhD
Steve Harte, PhD
Eric Ichesco, BS
Ann Oldendorf, MD
Katherine A. Scott, RN, BSN
David A. Williams, PhD

University of Washington, Seattle Discovery Site
Dedra Buchwald, MD, Director
Nilooafar Afari, PhD, Univ. Of California, San Diego
John Krieger, MD
Jane Miller, MD
Stephanie Richey, BS
Susan O. Ross, RN, MN
Roberta Spiro, MS
TJ Sundsvold, MPH
Eric Strachan, PhD
Claire C. Yang, MD

Washington University, St. Louis Discovery Site
Gerald L. Andriole, MD, Co-Director
H. Henry Lai, MD, Co-Director
Rebecca L. Bristol, BA, BS, Coordinator
Graham Colditz, MD, DrPH
Georg Deutsch, PhD, Univ. of Alabama at Birmingham
Vivien C. Gardner, RN, BSN, Coordinator
Robert W. Gereau IV, PhD
Jeffrey P Henderson, MD, PhD
Barry A. Hong, PhD, FAACP
Thomas M. Hooton, MD, Univ. of Miami
Timothy J. Ness, MD, PhD, Univ. of Alabama at Birmingham
Carol S. North, MD, MPE, Univ. Texas Southwestern
Theresa M. Spitznagle, PT, DPT, WCS
Siobhan Sutcliffe, PhD, ScM, MHS

University of Pennsylvania Data Coordinating Core (DCC)
J. Richard Landis, PhD, Core Director
Ted Barrell, BA
Philip Hanno, MD
Xiaoling Hou, MS
Tamara Howard, MPH
Michel A. Pontari, MD
Nancy Robinson, PhD
Alisa Stephens, PhD
Yanli Wang, MS

University of Colorado Denver Tissue Analysis & Technology Core (TATC)
M. Scott Lucia, MD, Core Director
Adrie van Bokhoven, PhD
Andrea A. Osypuk, BS
Robert Dayton, Jr
Karen R. Jonscher, PhD
Holly T. Sullivan, BS
R. Storey Wilson, MS

Additional Sites: Drexel University College of Medicine
Garth D. Ehrlich, PhD

Harvard Medical School/Boston Children’s Hospital
Marsha A. Moses, PhD, Director
Andrew C. Briscoe
David Briscoe, MD
Adam Curatolo, BA
John Froehlich, PhD
Richard S. Lee, MD
Monisha Sachdev, BS
Keith R. Solomon, PhD
Hanno Steen, PhD

Stanford University
Sean Mackey, MD, PhD, Director
Epifanio Bagarinoa, PhD
Lauren C. Foster, BA
Emily Hubbard, BA
Kevin A. Johnson, PhD, RN
Katherine T. Martucci, PhD
Rebecca L. McCue, BA
Rachel R. Moerriicke, MA
Aneesha Nilakantan, BA
Noorulain Noor, BS

Queens University
J. Curtis Nickel, MD, FRCSC, Director

National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH)
Chris Mullins, PhD
John W. Kusek, PhD
Ziya Kirkali, MD

Abbreviations
BACH: Boston area community health survey; BPS: Bladder pain syndrome; CFS: Chronic fatigue syndrome; CNS: Central nervous system; CPC: Chronic prostatitis cohort; CP/CPPS: Chronic prostatitis/chronic pelvic pain syndrome; DCC: Data coordinating core; DNA: Deoxyribonucleic acid; EEP: External experts panel; FM: Fibromyalgia; IBS: Irritable bowel syndrome; IC/BPS: Interstitial cystitis/bladder pain syndrome; ICCRN: Interstitial cystitis collaborative research network; ICCTG: The interstitial cystitis clinical trials group; ICDB: Interstitial cystitis database study; LONI: Laboratory of neuroimaging; MAPP: Multidisciplinary approach to the study of chronic pelvic pain; MR/ fMRI: Magnetic resonance imaging/functional magnetic resonance imaging; NIDDK: The national institute of diabetes, digestive, and kidney diseases; NUAS: Non-urologic associated syndromes; PPT: Pressure pain threshold; RICE: RAND IC epidemiology study; TATC: Tissue analysis and technology core; Trans-MAPP: EP: Trans-MAPP epidemiology and phenotyping study; UCLA: University of California at Los Angeles et al. BMC Urology 2014, 14:57
http://www.biomedcentral.com/1471-2490/14/57
Angeles; UCPPS: Urological chronic pelvic pain syndromes; VB1, VB2: Voided bladder 1, 2.

Competing interests
QJ Clemens, C Mullins, JW Kusek, Z Kirkali, EA Mayer, LV Rodriguez, AJ Schaeffer, D Buchwald, and JR Landis declare no competing interests. DJ Klumpo declares ownership and equity interests in ProbiTox Inc, and Gold Coast Therapeutics Inc. KJ Kredor is a Consultant for Medtronic, Astellas, Symptelligence, and Tengion. GL Andriole is a Consultant for Augmenix, Bayer, Genomic Health, GlaxoSmithKline and Myriad Genetics and has received research grants from Johnson & Johnson, Johnson, Medication and Wilex. MS Lucia declares ownership of 3D Biopsy and has consulted for Myriad Genetics and Bayer Healthcare. DJ Clauw has received grants from Pfizer, Cerepex, Lilly, Merck, Nuvo and Furest, and Consulting Fees and Honoraria from Pfizer, Cerepex, Lilly, Merck, Nuvo, Furest, and Theranueva, and Johnson & Johnson.

Authors' contributions
QJC wrote the initial draft manuscript. All authors read and approved the final manuscript.

Acknowledgements
The MAPP Research Network acknowledges support through NIH grants: U01 DK82315, U01 DK82316, U01 DK82325, U01 DK82333, U01 DK82342, U01 DK82344, U01 DK82345, and U01 DK82370. The NIDDK and MAPP Network investigators wish to thank the Interstitial Cystitis Association (ICA) and the Prostatitis Foundation (PF) for their assistance in study participant recruitment and other network efforts. We thank the participants and staff from the following sites that participated in the study: Northwestern University; University of California, Los Angeles; University of Iowa; Washington University, St. Louis; University of Washington, Seattle; University of Michigan; University of Pennsylvania (Data Coordinating Core); University of Colorado Denver (Tissue Analysis & Technology Core); Stanford University; NIDDK. This article outlines independent research commissioned by the National Institute for Health (NIH). The views expressed in this article are those of the author(s) and are not necessarily those of the NIH, the NIDDK, or the Department of Health and Human Services (DHHS).

Author details
1Department of Urology, University of Michigan, Ann Arbor, MI, USA. 2National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA. 3Division of Digestive Diseases, University of California, Los Angeles, CA, USA. 4Department of Urology, Northwestern University, Chicago, IL, USA. 5Department of Urology, University of Iowa, Iowa City, IA, USA. 6Departments of Epidemiology and Medicine, University of Washington, Seattle, WA, USA. 7Department of Urologic Surgery, Department of Surgery, Washington University School of Medicine, St Louis, MO, USA. 8Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. 9Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. 10Departments of Anesthesiology and Medicine, University of Michigan, Ann Arbor, MI, USA.

Received: 18 June 2014 Accepted: 23 July 2014
Published: 1 August 2014

References
1. Bogart LM, Berry SH, Clemens QJ. Symptoms of interstitial cystitis, painful bladder syndrome and similar diseases in women: a systematic review. J Urol 2007, 177(2):450–456.
2. Clemens QJ, Markossian TW, Meenan RT, O’Keeffe Rossetti MC, Calhoun EA: Overlap of voiding symptoms, storage symptoms and pain in men and women. J Urol 2007, 178(4 Pt 1):1354–8. discussion 1358.
3. Simon LJ, Landis JR, Erickson DR, Nyberg LM. The interstitial cystitis data base study: concepts and preliminary baseline descriptive statistics. Urology 1997, 49(SA Suppl):64–75.
4. Propert KJ, Schaeffer AJ, Brensinger CM, Kusek JW, Nyberg LM, Landis JR: A prospective study of interstitial cystitis: results of longitudinal followup of the interstitial cystitis data base cohort: the interstitial cystitis data base study group. J Urol 2000, 163(3):1434–1439.
5. Sant GR, Propert KJ, Hanno PM, Burns D, Culkin D, Diokno AC, Hardy C, Landis JR, Mayer R, Madigan R, Messing EM, Peters K, Theoharides TC, Warren J, Wein AJ, Steers W, Kusek JW, Nyberg LM. Interstitial Cystitis Clinical Trials Group: A pilot clinical trial of oral pentosan polysulfate and oral hydroxyazine in patients with interstitial cystitis. J Urol 2003, 170(3):810–815.
6. Mayer R, Propert KJ, Peters KM, Payne CK, Zhang Y, Burns D, Culkin DJ, Diokno A, Hanno P, Madigan R, Messing EM, Nickel JC, Sant GR, Warren J, Wein AJ, Kusek JW, Nyberg LM, Foster HE. Interstitial Cystitis Clinical Trials Group: A randomized controlled trial of intravesical bacillus calmette-guerin for treatment refractory interstitial cystitis. J Urol 2005, 173(4):1186–1191.
7. Propert KJ, Mayer RD, Wang Y, Sant GR, Hanno PM, Peters KM, Kusek JW. Interstitial Cystitis Clinical Trials Group: Responsiveness of symptom scales for interstitial cystitis. Urology 2006, 67(1):55–59.
8. Propert KJ, Mayer R, Nickel JC, Payne CK, Peters KM, Teal V, Burns D, Kusek JW, Nyberg LM, Foster HE, Interstitial Cystitis Clinical Trials Group: Did patients with interstitial cystitis who failed to respond to initial treatment with bacillus calmette-guerin or placebo in a randomized clinical trial benefit from a second course of open label bacillus calmette-guerin? J Urol 2007, 178(3 Pt 1):886–90.
9. Propert KJ, Mayer R, Nickel JC, Payne CK, Peters KM, Teal V, Burns D, Kusek JW, Nyberg LM, Foster HE, Interstitial Cystitis Clinical Trials Group: Followup of patients with interstitial cystitis responsive to treatment with intravesical bacillus Calmette-Guerin or placebo. J Urol 2008, 179(2):552–555.
10. Foster HE, Hanno PM, Nickel JC, Payne CK, Mayer RD, Burns DA, Yang CC, Chai TC, Kredor K, Peters KM, Lukacz ES, Fitzgerald MP, Cen L, Landis JR, Propert KJ, Yang W, Kusek JW, Nyberg LM. Interstitial Cystitis Collaborative Research Network: Effect of amitriptyline on symptoms in treatment naïve patients with interstitial cystitis/painful bladder syndrome. J Urol 2010, 183(3):1853–1858.
11. Yang CC, Burns DA, Propert KJ, Mayer RD, Peters KM, Nickel JC, Payne CK, Fitzgerald MP, Hanno PM, Chai TC, Kredor K, Lukacz ES, Foster HE, Cen L, Landis JR, Kusek JW, Nyberg LM. Interstitial Cystitis Collaborative Research Network: Early termination of a trial of mycophenolate mofetil for treatment of interstitial cystitis/painful bladder syndrome: lessons learned. J Urol 2011, 185(1):901–906.
12. Fitzgerald MP, Payne CK, Lukacz ES, Yang CC, Peters KM, Chai TC, Nickel JC, Hanno PM, Kredor K, Burns DA, Mayer R, Kotarinos R, Fortman C, Allen TM, Fraser L, Mason-Cover M, Furey C, Odabachian L, Sanfield A, Chu J, Huestis K, Tata GE, Dugan N, Sheth H, Bewyer K, Anaeme A, Newton K, Featherstone W, Halle-Podell R, Cen L, Landis JR, Propert KJ, Foster HE, J Kusek JW, Nyberg LM. Interstitial Cystitis Collaborative Research Network: Randomized multicenter clinical trial of myofascial physical therapy in women with interstitial cystitis/painful bladder syndrome and pelvic floor dysfunction. J Urol 2012, 186(6):2113–2121.
13. Schaeffer AJ, Landis JR, Knauss JS, Propert KJ, Alexander RB, Litwin MS, Nickel JC, O’Leary MP, Nadler RB, Pontari MA, Shoskes DA, Zeitlin SI, Fowler JE Jr, Mazurick CA, Kishel L, Kusek JW, Nyberg LM, Chronic Prostatitis Collaborative Research Network Group: Demographic and clinical characteristics of men with chronic prostatitis: the National Institutes of Health chronic prostatitis cohort study. J Urol 2002, 168(2):593–598.
14. Alexander RB, Propert KJ, Schaeffer AJ, Landis JR, Nickel JC, O’Leary MP, Pontari MA, McNaughton-Collins M, Shoskes DA, Comiter CV, Datta NS, Feaster DJ, Nadler RB, Zeitlin SJ, Knauss JS, Wang Y, Kusek JW, Nyberg LM, Litwin MS, Chronic Prostatitis Collaborative Research Network: Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double-blind trial. Int J Med 2004, 141(5):581–589.
15. Nickel JC, Krieger JN, McNaughton-Collins M, Anderson RJ, Pontari M, Shoskes DA, Litwin MS, Alexander RB, Berger R, Nadler R, O’Leary M, Liong ML, Zeitlin S, Chaiu S, Landis JR, Kusek JW, Nyberg LM, Schaeffer AJ, Chronic Prostatitis Collaborative Research Network Group: Aflunazosin and symptoms of chronic prostatitis-chronic pelvic pain syndrome. N Engl J Med 2008, 359(25):2663–2673.
16. Nickel JC, Alexander RB, Anderson DR, Berger R, Comiter CV, Datta NS, Fowler JE, Krieger JN, Landis JR, Litwin MS, McNaughton-Collins M, O’Leary MP, Pontari MA, Schaeffer AJ, Shoskes DA, White P, Kusek J, Nyberg L. Chronic Prostatitis Collaborative Research Network Study Group: Category III chronic prostatitis/ chronic pelvic pain syndrome: insights from the National Institutes of Health Chronic Prostatitis Collaborative Research Network studies. Curr Urol Rep 2008, 9(4):320–327.
Overlapping conditions in women with irritable bowel syndrome: a randomized controlled trial. Heitkemper M, Jarrett M.

17. FitzGerald MP, Anderson RJ, Potts J, Payne CK, Peters KM, Clemens JQ, Kotarinos R, Fraser L, Cosby A, Fortman C, Neville C, Badillo S, Oubadachian L, Sanfield A, O’Dougherty B, Hall-Podell R, Cen L, Chuai S, Landis JR, Cen L, Proppert KJ, Kusek JW, Nyberg LM Jr, Schaeffer AJ, Chronic Prostatitis Collaborative Research Network-2: Pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome: a randomized controlled trial. J Urol. 2010, 180(4):1586–1593.

18. Pontari MA, Krieger JN, Litwin MS, Anderson RU, Potts J, Payne CK, Peters KM, Clemens JQ, Sanfield A, Oubadachian L, Sanfield A, O’Dougherty B, Hall-Podell R, Cen L, Chuai S, Landis JR, Nickelberg K, Barrell T, Kusek JW, Nyberg LM. Randomized multicenter feasibility trial of myofascial physical therapy for the treatment of urological chronic pelvic pain syndromes. J Urol. 2013, 189(5):1575–1585.

19. Clemens JQ, Link CL, Eggers PW, Kusek JW, Nyberg LM Jr, McKinlay JB. BACH Survey Investigators: Prevalence of painful bladder symptoms and effect on quality of life in black, Hispanic and white men and women. J Urol. 2007, 177(4):1390–1394.

20. Link CL, Pulliam SJ, Hanno PM, Hall SA, Eggers PW, Kusek JW, McKinlay JB. Prevalence and psychosocial correlates of symptoms suggestive of painful bladder syndrome: results from the Boston area community health survey. J Urol. 2008, 180(2):599–606.

21. Berry SH, Elliott MN, Suttorp MJ, Clemens JQ. Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States. J Urol. 2011, 186(2):540–544.

22. Suskind AM, Berry SH, Ewing BA, Elliott MN, Suttorp MJ, Clemens JQ. The prevalence and overlap of interstitial cystitis/bladder pain syndrome and chronic prostatitis/chronic pelvic pain syndrome in men: results of the RAND Interstitial Cystitis Epidemiology male study. J Urol. 2013, 189(1):141–145.

23. Warren JW, Howard FM, Cross RK, Good JL, Weissman MM, Wesselmann U, Langenberg P, Greenberg P, Clauw DJ. Antecedent nonbladder syndromes in case–control study of interstitial cystitis/painful bladder syndrome. Urology. 2009, 73(3):552–57.

24. Clauw DJ, Schmidt M, Radulovic D, Singer A, Katz P, Bresette J. The relationship between fibromyalgia and interstitial cystitis. J Psychiatr Res. 1997, 31(1):125–131.

25. Heitkemper M, Jarrett M. Overlapping conditions in women with irritable bowel syndrome. Urol Nurs 2009, 25(1):25–30. quiz 31.

26. Aaron LA, Herrell R, Ashton S, Belcourt M, Schmaling K, Goldberg J, Berry SH, Elliott MN, Suttorp MJ, Clemens JQ. Case–control study of medical comorbidities in women with interstitial cystitis. J Urol. 2008, 179(8):2222–2225.

27. Rodriguez MA, Afari N, Buchwald DS, National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Urological Chronic Pelvic Pain: Evidence for overlap between urological and nonurological unexplained clinical conditions. J Urol. 2009, 182(5):2123–2131.

28. Nickell JC, Shoskes DA, Dolinga R, Prots D. Clinical phenotyping of patients with chronic prostatitis/chronic pelvic pain syndrome and correlation with symptom severity. Urology. 2009, 73(3):538–42. discussion 542–3.

29. Shoskes DA, Nickell JC, Dolinga R, Prots D. Clinical phenotyping of patients with interstitial cystitis/painful bladder syndrome: a key to classification and potentially improved management. J Urol. 2009, 182(1):155–160.

Cite this article as: Clemens et al.: The MAPP research network: a novel study of urologic chronic pelvic pain syndromes. BMC Urology 2014 14:57.